Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(03): 141-145
DOI: 10.4103/0971-5851.190355
ORIGINAL ARTICLE

HIV-associated hematologic malignancies: Experience from a Tertiary Cancer Center in India

Rakesh Reddy
Department of Medical Oncology, Institute Rotary Cancer Hospital, AllInstitute of Medical Sciences, New Delhi, India
,
Ajay Gogia
Department of Medical Oncology, Institute Rotary Cancer Hospital, AllInstitute of Medical Sciences, New Delhi, India
,
Lalit Kumar
Department of Medical Oncology, Institute Rotary Cancer Hospital, AllInstitute of Medical Sciences, New Delhi, India
,
Atul Sharma
Department of Medical Oncology, Institute Rotary Cancer Hospital, AllInstitute of Medical Sciences, New Delhi, India
,
Sameer Bakhshi
Department of Medical Oncology, Institute Rotary Cancer Hospital, AllInstitute of Medical Sciences, New Delhi, India
,
Mehar C Sharma
Department of Pathology, AllInstitute of Medical Sciences, New Delhi, India
,
Saumyaranjan Mallick
Department of Pathology, AllInstitute of Medical Sciences, New Delhi, India
,
Ranjit Sahoo
Department of Medical Oncology, Institute Rotary Cancer Hospital, AllInstitute of Medical Sciences, New Delhi, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Context and Aim: Data on HIV associated hematologic malignancies is sparse from India. This study attempts to analyze the spectrum and features of this disease at a tertiary cancer center in India. Setting and Methods: Retrospective study from case records of patients registered with a diagnosis of hematologic malignancy and HIV infection between January 2010 and June 2015. Results: Thirteen cases of HIV associated hematologic malignancies were identified, six of them pediatric. HIV diagnosis was concurrent to diagnosis of cancer in 12 and preceded it in one of them. ECOG PS at presentation was >1 in all of them. All patients, except one, had B symptoms. Six of the patients had bulky disease and six are stage 4. Predominant extranodal disease was seen in 67% of them. NHL accounted for 10 of 13 patients and DLBCL-Germinal center was the most common subtype. Mean CD4+ cell count was 235/μL (range, 32-494). HAART could be given along with chemotherapy to 11 patients. Two-thirds of patients received standard doses of therapy. Chemo-toxicity required hospitalization in 58%. CR was achieved in 45% and 36% had progressive disease with first-line therapy. At the time of last follow up, 3 patients were alive with responsive disease, 2 in CR and 1 in PR. None of the pediatric patients were long time responders. Conclusions: These malignancies were of advanced stage and higher grade. Goal of therapy, in the HAART era, is curative. Pediatric patients had dismal outcome despite good chemotherapy and HAART. There is an urgent need to improve data collection for HIV related cancers in India.

Keywords

AIDS-related lymphoma - diffuse large B-cell lymphoma - highly active anti-retroviral therapy - HIV-related cancer in India - pediatric HIV malignancies


Publication History

Article published online:
12 July 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bonnet F, Chêne G. Evolving epidemiology of malignancies in HIV. Curr Opin Oncol 2008;20:534-40.
  • 2 NACO Annual Report 2014-2015. Available from: . [Last cited on 2015 Sep 08].
  • 3 Sharma SK, Kadhiravan T, Banga A, Goyal T, Bhatia I, Saha PK. Spectrum of clinical disease in a series of 135 hospitalised HIV-infected patients from North India. BMC Infect Dis 2004;4:52.
  • 4 Dhir AA, Sawant SP. Malignancies in HIV: The Indian scenario. Curr Opin Oncol 2008;20:517-21.
  • 5 Dhir AA, Sawant S, Dikshit RP, Parikh P, Srivastava S, Badwe R, et al.. Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control 2008;19:147-53.
  • 6 Venkatesh KK, Saghayam S, Devaleenal B, Poongulali S, Flanigan TP, Mayer KH, et al.. Spectrum of malignancies among HIV-infected patients in South India. Indian J Cancer 2012;49:176-80.
  • 7 Agarwal B, Ramanathan U, Lokeshwas N, Nair R, Gopal R, Bhatia K, et al.. Lymphoid neoplasms in HIV-positive individuals in India. J Acquir Immune Defic Syndr 2002;29:181-3.
  • 8 Sharma A, Bajpai J, Raina V, Mohanti BK. HIV-associated non-Hodgkin's lymphoma: Experience from a regional cancer center. Indian J Cancer 2010;47:35-9.
  • 9 Sachdeva RK, Sharma A, Wanchu A, Malhotra P, Varma S. Hematological malignancies in human immunodeficiency virus-positive individuals in North India. Leuk Lymphoma 2011;52:1597-600.
  • 10 Julka PK, Manoharan N, Rath GK, editors. Cancer Incidence and Mortality in Delhi UT Urban, 2010. Delhi Cancer Registry, Dr. BRA Institute Rotary Cancer Hospital, AIIMS, New Delhi; 2010.
  • 11 Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, et al.. Changing patterns of cancer incidence in the early- and late-HAART periods: The Swiss HIV Cohort Study. Br J Cancer 2010;103:416-22.
  • 12 Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: From epidemiology to therapeutic challenges. AIDS 2014;28:453-65.
  • 13 Levine AM. Acquired immunodeficiency syndrome-related lymphoma: Clinical aspects. Semin Oncol 2000;27:442-53.
  • 14 Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Châtelet FP, et al.. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-44.
  • 15 Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Incidence, presentation, treatment, and survival. Cancer 2006;106:128-35.
  • 16 Chow KU, Mitrou PS, Geduldig K, Helm EB, Hoelzer D, Brodt HR. Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2001;41:105-16.
  • 17 Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U, et al.. Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413-20.
  • 18 Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, et al.. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: Incidence and evolution of CD4+ T-cell lymphocytes. Blood 2011;117:6100-8.
  • 19 Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al.. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008;148:728-36.
  • 20 Little RF, Dunleavy K. Update on the treatment of HIV-associated hematologic malignancies. Hematology Am Soc Hematol Educ Program 2013;2013:382-8.
  • 21 Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, et al.. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.
  • 22 Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, et al.. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221-8.
  • 23 Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer 2012;118:3977-83.
  • 24 Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, et al.. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010;115:3008-16.
  • 25 Castillo JJ, Furman M, Beltrán BE, Bibas M, Bower M, Chen W, et al.. Human immunodeficiency virus-associated plasmablastic lymphoma: Poor prognosis in the era of highly active antiretroviral therapy. Cancer 2012;118:5270-7.
  • 26 Granovsky MO, Mueller BU, Nicholson HS, Rosenberg PS, Rabkin CS. Cancer in human immunodeficiency virus-infected children: A case series from the Children's Cancer Group and the National Cancer Institute. J Clin Oncol 1998;16:1729-35.
  • 27 Caselli D, Klersy C, de Martino M, Gabiano C, Galli L, Tovo PA, et al.. Human immunodeficiency virus-related cancer in children: Incidence and treatment outcome – Report of the Italian Register. J Clin Oncol 2000;18:3854-61.
  • 28 Mueller BU. Cancers in children infected with the human immunodeficiency virus. Oncologist 1999;4:309-17.
  • 29 Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, et al.. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol 2012;30:4111-6.
  • 30 Suneja G, Shiels MS, Angulo R, Copeland GE, Gonsalves L, Hakenewerth AM, et al.. Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol 2014;32:2344-50.